Tolerability and efficacy of sodium-glucose co-transporter-2 inhibitors in Australian Aboriginal and Torres Strait Islanders with type 2 diabetes mellitus: an observational study.

Noor FishanKurt TowersJavier HauratAnthony ZimmermannAnjana Radhakutty

Published in: Internal medicine journal (2023)

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have renal and cardiovascular benefits in addition to their glucose-lowering potential. Data on the efficacy and safety of SGLT2i in Australian Aboriginal and Torres-Strait Islanders are lacking. We conducted a single-centre retrospective study assessing the safety and effects on glycaemic control and albuminuria of SGLT2i in Aboriginal and Torres Strait Islander patients with type 2 diabetes mellitus.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
type diabetes
chronic kidney disease
prognostic factors
electronic health record
open label
big data
clinical trial
machine learning
skeletal muscle
weight loss
risk assessment
double blind
patient reported